Septerna (NASDAQ:SEPN) COO Sells $149,640.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $37.41, for a total transaction of $149,640.00. Following the transaction, the chief operating officer owned 174,209 shares in the company, valued at $6,517,158.69. The trade was a 2.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Elizabeth Bhatt also recently made the following trade(s):

• On Tuesday, August 11th, Elizabeth Bhatt sold 25,000 shares of Septerna stock. The shares were sold at an average price of $44.00, for a total value of $1,100,000.00.

Septerna Stock Up 0.1%

SEPN stock traded up $0.03 during midday trading on Monday, reaching $36.38. The company’s stock had a trading volume of 410,189 shares, compared to its average volume of 416,043. Septerna, Inc. has a 52 week low of $17.55 and a 52 week high of $51.10. The business’s 50-day simple moving average is $39.25 and its 200-day simple moving average is $33.66. The stock has a market cap of $1.70 billion, a PE ratio of -67.37 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. The business had revenue of $26.75 million during the quarter, compared to the consensus estimate of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. As a group, equities analysts forecast that Septerna, Inc. will post -1.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SEPN has been the topic of a number of recent research reports. Wells Fargo & Company lifted their price objective on shares of Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Stifel Nicolaus set a $49.00 target price on Septerna in a report on Tuesday, August 11th. Truist Financial boosted their price objective on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. JPMorgan Chase & Co. upped their target price on Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, August 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.44.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Engineers Gate Manager LP raised its stake in Septerna by 5.0% in the second quarter. Engineers Gate Manager LP now owns 17,350 shares of the company’s stock worth $581,000 after buying an additional 822 shares in the last quarter. Strs Ohio increased its stake in Septerna by 17.8% during the 1st quarter. Strs Ohio now owns 17,200 shares of the company’s stock valued at $413,000 after purchasing an additional 2,600 shares in the last quarter. Squarepoint Ops LLC lifted its position in Septerna by 17.3% in the 2nd quarter. Squarepoint Ops LLC now owns 21,219 shares of the company’s stock valued at $711,000 after acquiring an additional 3,136 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Septerna during the fourth quarter valued at $88,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Septerna by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock worth $1,411,000 after acquiring an additional 3,377 shares during the period.

Septerna Company Profile

Septerna, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing oral medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Complex Platform to study GPCRs in their native state and identify small-molecule medicines for targets that have historically been difficult to address.